The likelihood of Alfasigma subsidiary Intercept Pharmaceuticals withdrawing its primary biliary cholangitis treatment Ocaliva (obeticholic acid) got stronger following the US regulator’s fourth safety alert since an accelerated approval in 2016.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?